Background-Early recurrence (ER) of atrial tachyarrhythmias during the first 3 months (blanking period) after atrial fibrillation ablation can be highly symptomatic, often requiring emergency treatment. Short-term steroid therapy may suppress ER during the blanking period. Methods and Results-We prospectively enrolled 138 patients who were randomly assigned to 2 groups (steroid group and control group). An intravenous bolus of 0.5 mg/kg of methylprednisolone for 2 days followed by 12 mg daily of oral methylprednisolone for 4 days was given to the steroid group patients. The primary end point was ER during the blanking period (3 months post ablation 
R adiofrequency catheter ablation (RFCA) is an effective therapeutic option for drug-refractory paroxysmal or persistent atrial fibrillation (AF). However, early recurrence (ER) after RFCA is relatively common. ER during the 3-month post ablation period, the so-called blanking period, is not considered to be a failure of AF ablation. 1, 2 The rate of ER during the blanking period is estimated to be as high as 37.8%. [3] [4] [5] In addition, ER can be highly symptomatic, and often requires electric cardioversion, hospitalization, or drug adjustment. Temporary use of antiarrhythmic drugs (AADs) has been shown to be well-tolerated and effective in preventing these ERs. 6 However, AADs have limited efficacy and can cause significant side effects. Inflammatory reactions are important in the ER of AF after catheter ablation, 7 and periprocedural anti-inflammatory drugs have multiple effects. They are expected to reduce tissue edema, and facilitate the recognition of a gap between RF lesions, by allowing easy exposure of the reconnected pulmonary vein (PV) during the procedure. In addition, suppression of pericardial inflammatory reactions in the early post-RF period may reduce atrial pericarditis-related AF recurrence. However, excessive suppression of the post-RF physiological inflammatory process may reduce a delayed extension of the RF lesion, which may facilitate a PV reconnection and cause late recurrence (LR). We investigated the efficacy of periprocedural short-term steroid therapy in preventing ER during the 3-month blanking period after AF ablation and LR during a 24-month follow-up period.
Methods

Study Population
The required sample size was calculated from the findings of previous research in which the rate of ER was 30% during the 3-month period. 5 To detect a decrease from 30% to 5% in the treatment group with a 20% dropout (at the 0.05 level of significance, statistical power 0.95, and sampling ratio 1:1), 64 patients were required in each group.
A total of 138 consecutive patients with symptomatic AF (108 paroxysmal AF and 30 persistent AF) and undergoing their first RFCA for AF were enrolled from March 2010 to January 2012. None had been included in any other clinical study. Patients with active inflammation, gastric ulcers or abnormal liver function, and current steroid users, were excluded ( Figure 1 ). All AADs were discontinued 5 half-lives before the ablation with the exception of amiodarone, which was discontinued for at least 4 weeks. This study was approved by the Institutional Review Board of Asan Medical Center, and all patients gave their written informed consent before participation.
Study Protocol
The study was designed as a prospective, randomized, single-blind study. The patients were randomized for treatment with steroids (steroid group) or a placebo (control group) on the first day of hospitalization. In the steroid group, 0.5 mg/kg of methylprednisolone sodium succinate (Methysol, Kunwha Pharmaceutical, Seoul, Korea) in 10 mL of 0.9% normal saline was administered intravenously shortly before the femoral vein puncture during the procedure (day 0) and the next day (day 1). Oral methylprednisolone (Methylon, Kunwha Pharmaceutical, Seoul, Korea) was administered (12 mg/d) for the following 4 days (days 2-5; 4 days). A placebo solution (0.9% normal saline, 10 mL) was administered to the control group in the same manner as the steroid (Figure 1) . A proton pump inhibitor (Nexium, AstraZeneca, London, United Kingdom) was given to the patients in both groups from the procedure day (day 0) to discharge.
Radiofrequency Catheter Ablation
Catheter ablation was performed with a 3.5-mm, irrigated-tip catheter, with the power and temperature generally limited to 30 W and 43°C, respectively. The RFCA was guided by a 3-dimensional mapping system, either EnStie NavX (St. Jude Medical, Minneapolis, MN) or Carto 3 (Biosense Webster Inc, Diamond Bar, CA) with computed tomographic image integration. PV isolation (PVI) was achieved with a wide antral ablation around the ipsilateral PVs. A cavotricuspid isthmus ablation was added for patients with typical atrial flutter. If the patient remained in AF after the PVI, linear lesions were created at the mitral isthmus and roof. After that, superior vena cava isolation was performed only in patients who had superior vena cava triggers recognized using pacing maneuvers or an isoproterenol infusion (≤3 μg/min). If at any point the AF organized into reentrant atrial tachycardia or a specific trigger, this was mapped and ablated. The procedural end points were noninducibility for paroxysmal AF, and AF termination for persistent AF. If sinus rhythm was not restored following all the above ablation methods, the patient was cardioverted with a direct current shock.
Postablation Follow-Up
Daily 12-lead ECGs and telemetry monitoring were used to check atrial arrhythmias until discharge. After discharge, daily ECGs were recorded with a handheld ECG device (Heartcall, Uheart, co Daegu, Korea) for 30 days after the RFCA. All patients were followed for 24 months (median, 24.9 months and interquartile range, 22.9 months). Patients were asked to visit an outpatient clinic at 1, 3, 6, and 12 months after the RFCA and then every 6 months thereafter; 12-lead ECGs, 24-hour Holter monitoring or a 7-day event recordings were used on the patients at every visit and whenever the patient complained of symptoms. AAD therapy during the blanking period was left to the discretion of the attending physicians. All patients continued oral anticoagulation for a minimum of 3 months. AF recurrence was defined as any episode of AF/atrial flutter/atrial tachycardia of at least 30 s in duration. (1) Immediate recurrence was defined as AF recurrence within 2 days post ablation, (2) 1-month recurrence was defined as an AF recurrence during 1-month post ablation period, (3) ER was defined as an AF recurrence within the blanking period (3 months post ablation), and (4) LR was defined as an AF recurrence during the 24-month follow-up period after the blanking period.
The primary end point of the study was the incidence of ER during the blanking period. The secondary end points were (1) the
WHAT IS KNOWN
• Early recurrence of atrial fibrillation (AF) during the 3-month post ablation period (a blanking period) after catheter ablation occurs in >30% of patients.
• Early recurrence of AF is sometimes highly symptomatic and requires therapeutic intervention (antiarrhythmic drugs, electric cardioversion, or hospitalization).
WHAT THE STUDY ADDS
• The periprocedural short-term moderate intensity steroid therapy significantly reduced the early recurrence of AF without any significant side effects of the steroid therapy, but it did not affect the long-term recurrence of AF after catheter ablation.
• The postablation inflammatory process may play a critical role in the early recurrence of AF during the blanking period. proportion of patients with clinical events (emergency department [ED] visits, hospitalization, electric cardioversion, and AAD adjustment for AF recurrence in the blanking period.) and (2) the LR during the 24-month follow-up and adverse events focused on gastrointestinal manifestations (epigastric discomfort and dyspepsia) and blood glucose levels. White blood cell (WBC) counts, body temperature (BT), and fasting glucose levels were checked for 2 consecutive days and at 4 weeks after the procedure.
Statistics
Continuous variables are presented as the mean±SD. Comparisons were made using the t test for normally distributed data and the Mann-Whitney U test for non-normally distributed data. Categorical data were compared using a Fisher exact test. KaplanMeier curves with a log-rank test were used to analyze the freedom from AF recurrence between the groups. Binary logistic regression and Cox regression analyses were carried out for the early and late AF recurrences after the AF ablation, respectively. Both univariate and multivariable regression models were fitted for identifying the unadjusted and adjusted steroid effect. In the multivariable regression, the final models were determined by a backward variable selection approach where the least significant variables were removed one by one after fitting a full nonparsimonious model. The candidate variables whose P values were <0.2 were selected in the univariate regression analyses. In the Cox PH model, the proportionality assumption was examined using the partial Schoenfeld residual test and no relevant violations were found. The linearity assumption in the final models was examined using the multivariable fractional polynomial model. 8 That model selected the multiple fractional polynomial models that best predicted the outcome. The model could accommodate a generalized linear model and proportional hazards model. On the basis of the fit results, no linearity assumptions were violated. Hence the variable transformation was not considered further. A statistical analysis was performed using R software version 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria) and Prism (Version 5.0; GraphPad Software Inc, La Jolla, CA). In particular, the R packages for the multivariable fractional polynomial and survival were used for the fractional polynomial model and survival data analysis. A P<0.05 was considered statistically significant.
Results
Baseline Characteristics
The baseline characteristics of the patients in the 2 groups are shown in Table 1 . There were no differences in the age, sex, underlying disease, AADs, and echocardiography parameters between the groups. PVI was successfully performed in all patients. There were no differences in additional linear ablation of the cavotricuspid isthmus, roof, perimitral isthmus, and superior vena cava isolation between the groups. Total procedure times, and fluoroscopic and RF ablation times were also similar.
AF Recurrence in the Blanking Period and the 24-Month Follow-Up Period
During the initial 3 months after the AF ablation, AF recurrence was significantly lower in the steroid group than in the control group (15/ Figure 2 ). The AF recurrences in the first 48 hours and in the first month after the AF ablation were numerically lower in the steroid group than in the control group (Figure 2) . The AF recurrence in the 3 months after the ablation was significantly lower in the steroid group than in the control group as demonstrated in the Kaplan-Meier analysis (log-rank test, P=0.007; Figure 3A ). In contrast, steroid therapy did not reduce LR during a mean 24.1±12.9 month follow-up period. The Kaplan-Meier curves for the long-term outcomes of AF ablation did not differ (log-rank test, P=0.918; Figure 3B ). During the blanking period, the composite incidence of clinical events was similar in the 2 groups (39.1% versus 50.0%, P=0.23; Table 2 ). One case of pericarditis occurred in the control group and was eventually treated with steroids. This patient was included in the control group for an intention-totreat analysis.
White Blood Cell Counts and the BT During Follow-Up
There were no differences between the groups about the baseline white blood cells and BT before the ablation (Table 3) . During the initial 2 days after the ablation, the white blood cell counts in the steroid group were lower than those in the 
Determinants of Early and Late Recurrence
A logistic regression analysis revealed that the steroid therapy reduced the ER during the blanking period (odds ratio, 0.441; 95% confidence interval [CI], 0.220-0.884; P=0.021; Table 4 ). The other clinical and procedural parameters were not associated with ER.
In a multiregression analysis, persistent AF (hazard ratio, 2.687; 95% CI, 1.176-6.137; P=0.019), hypertension (hazard ratio, 2.819; 95% CI, 1.230-6.463; P=0.014), and the LVEF (hazard ratio, 0.922; 95% CI, 0.856-0.993; P=0.033) were associated with LR during the long-term follow-up period (Table 5 ). Steroid therapy did not decrease the LR during this period (hazard ratio, 1.147; 95% CI, 0.577-2.277; P=0.696).
Discussion
In this study, we made the following observations:
1. Periprocedural short-term moderate intensity steroid therapy reduced ER during the 3-month period after the AF ablation. 2. This reduction in the ER was not associated with a reduction in clinical events (ED visits, electric cardioversion, hospitalization, and AAD adjustments) during the blanking period. 3. The steroid therapy did not improve the 24-month outcomes.
The Causes of ER During the Blanking Period
ER after AF ablation is relatively common. For a blanking period of 3 months, the rate of ER has been estimated to be 37.8% (9 studies; 2190 patients; 95% CI, 35.7%-39.8%). 5 There may be several causes of ER: (1) recovery of PV conduction because of a nontransmural RF lesion, (2) the postablation inflammatory process (3), a transient imbalance of the A B Figure 3 . Freedom from atrial fibrillation (AF) recurrence during the follow-up period. Steroid therapy reduced early recurrence (A) in the blanking period (log-rank test, P=0.007). In contrast, it had no effect on late recurrence (B; log-rank test, P=0.918).
autonomic nerve system acting as an arrhythmia trigger, and (4) a lack of delayed RF lesion formation. Most AF recurrences after PVI are associated with PV reconnections. Gaps in the RF lesion lines can be proarrhythmic, acting as zones of slow conduction, and facilitating reentry. 9 Nontransmural, noncontinuous lesions represent the inherent limitations of RFCA. The second most prominent cause of ER, postablation inflammation, contributes to the heterogeneity of action potential durations in the myocardium of the atrial or PVs in response to inflammatory cytokines. This may ultimately result in the creation of an arrhythmogenic substrate that is related to the initiation of AF. 10, 11 Recently, a 3-month course of colchicine therapy after the AF ablation was shown to reduce the levels of inflammatory cytokines, specifically the C-reactive protein and interleukin-6 (IL-6). In that study, AF recurrence during a 3-month followup was observed in 33.5% of the placebo group and 16% of the colchicine group. 12 In the third cause of AF recurrence, RF applications lead to some modification of the autonomic nerve system, either by enhancing the sympathetic tone or by reducing the parasympathetic tone. 13 As for the final cause, several studies have revealed a delayed effect of RF energy involving the progressive growth of ablation lesions 14, 15 and scar maturation during the first 3 months. 16, 17 Inadequate scarring from the ablation procedure is likely to result in ER.
Steroid Therapy to Prevent AF Recurrence After Ablation
Proinflammatory processes are known to be a major cause of early AF recurrence. 18 The local inflammation and tissue edema created by the myocardial damage resulting from RF ablation may play prominent roles in provoking ER. 19 In a randomized controlled trial 20 in patients with paroxysmal AF, short-term steroid therapy after the PVI was effective in preventing AF recurrence not only in the immediate period (within 3 days) but also in the midterm (14 months). This more prolonged beneficial effect is in sharp contrast to our results, and may be a consequence of a difference in the definition of the blanking period. In the report by Koyama et al 20 , the definition of the blanking period was only 1 month and the Kaplan-Meier curves for the 2 groups diverged only during the first 3 months, with little difference later (3-14 month) . Consequently the 2 studies may reflect a similar effect of the steroid therapy on post-RF recurrence.
Steroid therapy is known to influence the acute local inflammatory process by reducing inflammatory cell recruitment and tissue edema around the RF lesion. This acute effect of steroid therapy results in a greater exposure of dormant PV conduction and reduces ablation gaps during PVI. A prospective study showed that a single intravenous bolus of 250 mg of hydrocortisone immediately after the trans-septal puncture unmasked dormant PV conduction by adenosine during the PVI. However, there was no difference in the segmental PV reconnections and 1-year freedom from AF recurrence between the steroid group and the control group. 21 Together with the inhibitory effects of steroids on local pericardial inflammation, this effect on PVs is expected to play an important role in reducing early post-RF AF recurrences. Steroid therapy may also reduces delayed scar formation during the healing process. This effect of steroids on scar maturation is achieved by inhibiting the proliferation of fibroblasts and promoting their apoptosis. 22 This may, however, be a double-edged sword, because although steroids may help to reduce abnormal uneven fibrosis (an anatomic substrate for focal triggering or microreentry). They may also inhibit the delayed extension of the RF lesion between the ablation points and promote LR. It is of note that the effect of steroids was more pronounced in the subset of patients who received additional lines than in the patients with PVI only or PVI and cavotricuspid isthmus ablation ( Figure I in the Data Supplement).
The Effective Dosage of Steroid Therapy for Preventing AF Recurrence
There are no data concerning the optimal dose of steroids for suppressing inflammatory reactions after AF ablation. We analyzed the dosages of steroids in the 3 previous studies and in this study (Table 6 ). In 2 cohort studies, 21 ,23 a single low dose of the steroid therapy (hydrocortisone <250 mg=methylprednisolone 50 mg) was insufficient to prevent postablation AF recurrence. In this study, the mean weight of the patients was 68.8±11.9 kg and 108 (78.3%) patients weighed >60 kg. Among those 108 patients, ER was higher in the control group than in the steroid group (P=0.003), whereas LR did not differ between the 2 groups (P=0.550). However, in the patients who weighed ≤60 kg (n=30), steroid therapy failed to reduce the ER or LR (Table I in the Data Supplement). This suggests that in patients weighing >60 kg, the total dose of the steroids for preventing the ER should be at least 540 mg of hydrocortisone (=methylprednisolone 110 mg) during the first 4 or 5 days post ablation.
Side Effects of Steroid Therapy
Gastrointestinal side effects (epigastric pain and dyspepsia) were the most common. All the patients were given a proton pump inhibitor for at least 7 days. Gastrointestinal symptoms were reported in 9 (14.1%) of the 64 patients in the steroid group versus 6 (8.1%) of the 74 patients in the control group (P=0.29). It is not clear whether the gastric symptoms resulted from the ablation procedure itself or from the steroid treatment. No cases of gastrointestinal bleeding were recorded. The proportion of patients with diabetes mellitus was similar between the 2 groups (12.5% versus 13.5%; P=1.00). The baseline fasting glucose levels and 4-week follow-up glucose levels also did not differ (Table 3 ). The maximal glucose levels monitored during admission were slightly higher in the steroid group than in the control group, but the effect was not statistically significant (P=0.055). However, no patients were given additional diabetic medications for blood glucose control, and none were diagnosed with newly developed diabetes mellitus during the 24-month follow-up. The hemoglobin A 1 C levels in the patients with diabetes mellitus did not differ between the groups (5.6±0.3 in the steroid group versus 5.8±0.5 in the control group, P=0.379)
Study Limitations
Our study had several limitations. First, it involved a relatively small number of patients despite the prospective, randomized study design. Second, some patients with asymptomatic AF recurrence might have been missed. However, the intensive followup protocol using a 1-month handheld device and a 7-day event recorder should have maximized the detection of AF recurrence. Third, inflammatory biomarkers, such as the C-reactive protein and IL-6 were not checked, but higher leukocyte counts and higher BTs have been shown to be independent predictors of AF recurrence after PVI; 7,20 hence, we presumed that the BT and leukocyte count were indirectly related to the inflammatory process after AF ablation. Finally, the largest effective dose of the steroids without adverse side effects cannot be determined from this study because it was not planned as a part of the study. Further investigation is needed to determine the optimal dose of steroids.
Conclusions
Periprocedural short-term, moderate intensity steroid therapy reduced the ER of AF during the blanking period. It may not be effective in preventing late recurrences of AF.
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